Regulatory Status AOD-9604 is not FDA-approved for any medical use and is listed by the FDA as a bulk drug substance that may present safety risks. Clinical development was halted after Phase IIb trials failed to meet efficacy endpoints. Summary AOD-9604 is a synthetic analog of the HGH 177191 fragment developed for fat-metabolism research
This may be due to copper's ability to enhance the expression of metalloproteinases (MMPs).16 MMPs normally regulate the degradation of collagen, and a specific one, MMP-1, may be responsible for the initiation of collagen fragmentation.17 Supporting this, a 2024 study noted that elevated MMP-1 levels appear to contribute to aging skin and that higher MMP-1 levels in mice led to:18 The loss and fragmentation of dermal collagen fibrils Contracted fibroblast morphology Reduced collagen production Increased expression of pro-inflammatory mediators Additionally, a 2016 study found that GHK-Cu significantly increased gene expression of MMP-1 and MMP-2 at the lowest concentration, which the studys authors considered to be one of the reasons the peptide was able to increase collagen and elastin production.19 So, what this could ultimately mean is that using too much GHK-Cu (or other copper peptides) may in theory increase the skins MMP-1 concentration above the levels involved in healthy collagen production, taking it into the collagen fragmentation and breakdown territory seen in older skin with naturally higher MMP-1 levels
A vial label may show the concentration, while your treatment plan may describe the amount used at each administration
Severe muscle weakness or cramping, which can be a sign of low potassium that needs treating
The tests can also give false readings where they do not assess the bioavailability of the B12 or whether it is functional or not
